WS #12006
Holding: newest synthesis is 129d 3h old
FDA approves Biogen's LEQEMBI IQLIK subcutaneous injection for early Alzheimer's, with US launch planned for late August 2026.
FDA Approval for Biogen Alzheimer's Drug
FDA approves Biogen's LEQEMBI IQLIK subcutaneous injection for early Alzheimer's, with US launch planned for late August 2026.